Drug-coated balloon versus drug-eluting stent in acute myocardial infarction
A protocol for systematic review and meta-analysis
Baoyu Geng, MMa, Zhe Liu, MMa, Guangzhi Feng, MMa, Jun Jiang, MMb,∗

Abstract
Background: Previous studies comparing the published literature on drug-eluting stents (DES) and drug-coated balloon (DCB) have drawn divergent conclusions, as these studies are limited by small sample sizes. To overcome these limitations, we thus conducted a high-quality systematic review and meta-analysis to assess the efficacy and safety of DCB versus DES for patients with acute myocardial infarction (AMI). It was hypothesized that DCB use at the AMI is associated with decreased risk of cardiovascular disease and death.

Methods: The electronic databases Embase, Medline, PubMed, and Cinahl were searched from the earliest available date until August 2021. Study included in our study had to meet all of the following inclusion criteria: all randomized controlled trials to assess the efficacy and safety of DES versus DCB in the treatment of AMI were considered eligible for analysis; participants received DCB or DES; reporting the available data on cardiac death, all-cause death, myocardial infarction, target lesion revascularization, target vessel revascularization, major adverse cardiac events, and stent thrombosis. Review Manager Software (v 5.3; Cochrane Collaboration) was used for the meta-analysis. Two of us independently assessed the risk of bias in the included studies using parameters defined in the Cochrane Handbook for Systematic Reviews of Interventions criteria.

Results: It was hypothesized that DCB use at the AMI is associated with decreased risk of cardiovascular disease and death.

Registration number: 10.17605/OSF.IO/AVTYW.

Abbreviations: AMI = acute myocardial infarction, DCB = drug-coated balloon, DES = drug-eluting stents.

Keywords: acute myocardial infarction, drug-coated balloon, drug-eluting stents, meta-analysis, protocol

1. Introduction
Cardiovascular disease is a leading cause of mortality and morbidity worldwide, with an estimated 8.14 million people worldwide died from acute myocardial infarction (AMI) in 2013.[1] Primary percutaneous coronary intervention with drug-eluting stents (DES) has become one of the commonly used methods for the treatment of ST-elevation myocardial infarction. The introduction of bare metal stents significantly reduced revascularization rates after primary percutaneous coronary intervention compared to standard balloon angioplasty alone. With the development of DES, these ratios fell even further.[2,3] However, routine stent placement did not mean a reduced rate of cardiac death or recurrent myocardial infarction. In addition, permanent vascular implants are associated with an increased risk of stent thrombosis, which impair the vasomotor function of the culprit coronary arteries.[4]

Considering the lack of superiority in terms of hard clinical endpoints and the potential short- and long-term drawbacks of stent implantation, angioplasty with drug-coated balloon (DCB) without stents is a good strategy for the treatment of AMI.[5] The advantage of DCB is that it provides a uniform drug distribution at a short sustained exposure and high topical drug dose, thus preventing the disadvantages of conventional old balloon angioplasty.[6] In addition, the need for stent implantation can avoid long-term drawbacks such as stent thrombosis and coronary vasomotor responses or vascular geometry disturbances. Finally, this strategy may reduce the long-term need for dual antiplatelet therapy.[7,8]

Several recent studies have showed that both DES and DCB outperform other AMI intervention strategies.[9,10] In addition, the recent European Society of Cardiology guidelines for myocardial revascularization also recommend DCB and DES for patients with AMI.[11] However, previous randomized controlled studies[6,12] and meta-analysis[13] comparing the published literature on DES and DCB have drawn divergent conclusions, as these studies are limited by small sample sizes. In
recent years, several large randomized controlled trials have been published. To overcome these limitations, we thus conducted a high-quality systematic review and meta-analysis to assess the efficacy and safety of DCB versus DES for patients with AMI. It was hypothesized that DCB use at the AMI is associated with decreased risk of cardiovascular disease and death.

2. Materials and methods

2.1. Data sources and search strategy

The systematic literature review was structured to adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, which included requirements deemed essential for the transparent reporting of results. The electronic databases Embase, Medline, PubMed, and Cinahl were searched from the earliest available date until August 2021. The concepts of population, intervention, control, outcome, and design were combined with the “AND” operator. The population was defined as participants with AMI. The intervention was defined as a participant receiving DCB. The control group was defined as participants receiving DES. The outcomes were cardiac death, all-cause death, myocardial infarction, target lesion revascularization, target vessel revascularization, major adverse cardiac events, and stent thrombosis. The design was a randomized controlled trial. All articles were imported into the bibliographic software and screened for duplicates. Two reviewers independently screened the title and abstract of each article using predetermined eligibility criteria. Reference lists of included articles were hand-searched and citation tracking applied using Google Scholar to identify any further articles for inclusion. The review protocol has been registered on Open Science Framework registries. Ethical approval and patient consent were not required because this study was a literature-based study.

2.2. Eligibility criteria

Study included in our study had to meet all of the following inclusion criteria: all randomized controlled trials to assess the efficacy and safety of DES versus DCB in the treatment of AMI were considered eligible for analysis; participants received DCB or DES; reporting the available data on cardiac death, all-cause death, myocardial infarction, target lesion revascularization, target vessel revascularization, major adverse cardiac events, and stent thrombosis. Studies with overlapping data or insufficient data to calculate or extract effect estimates would be excluded. Case reports, biochemical trials, letters, and reviews would also be eliminated.

2.3. Data extraction

The data was extracted in duplicate. The reasons of exclusion at this stage were summarized. Results were recorded on trial data extraction forms and Excel spreadsheets. Data extracted related to: country and study date; participants (indication, age, sex); inclusion and exclusion criteria; intervention content and control group; setting, timing, duration and intensity of the intervention; follow-up time; subsequent losses and their causes; and the outcomes. For the results reported as continuous variables, the mean and standard deviation were extracted. If the results were reported as mean and confidence intervals, or median and quartile spacing, the appropriate conversion would be applied. If necessary, the lead author of the study would be contacted for missing data. We also asked whether any results not reported in their publications had been collected. If the author had provided information to other reviewers, the data would be included in our analysis and acknowledged appropriately.

2.4. Statistical analysis

Review Manager Software (v 5.3; Cochrane Collaboration) was used for the meta-analysis. Extracted data were entered into Review Manager by the first independent author and checked by the second independent author. Risk ratio with a 95% confidence interval or standardized mean difference with 95% CI were assessed for dichotomous outcomes or continuous outcomes, respectively. The heterogeneity was assessed by using the Q test and I² statistic. An I² value of <25% was chosen to represent low heterogeneity and an I² value of >75% to indicate high heterogeneity. All outcomes were pooled on random-effect model. A P value of <.05 was considered to be statistically significant.

2.5. Study quality assessment

Two of us independently assessed the risk of bias in the included studies using parameters defined in the Cochrane Handbook for Systematic Reviews of Interventions criteria. Differences were resolved through discussion and consensus among reviewers. Based on the information provided by the included studies, each item was recorded as high risk of bias, low risk of bias, or unclear. Two reviewers independently assessed the quality of the body of evidence for different outcomes using the grades of recommendation, assessment, development, and evaluation approach, a proven and widely practiced tool for assessing the quality of scientific evidence. Based on the grades of recommendation, assessment, development, and evaluation approach, we assessed 5 areas, ranking the strength of evidence for each result.

3. Discussion

Several recent studies have showed that both DES and DCB outperform other AMI intervention strategies. In addition, the recent European Society of Cardiology guidelines for myocardial revascularization also recommend DCB and DES for patients with AMI. However, previous randomized controlled studies and meta-analysis comparing the published literature on DES and DCB have drawn divergent conclusions, as these studies are limited by small sample sizes. In recent years, several large randomized controlled trials have been published. To overcome these limitations, we thus conducted a high-quality systematic review and meta-analysis to assess the efficacy and safety of DCB versus DES for patients with AMI. It was hypothesized that DCB use at the AMI is associated with decreased risk of cardiovascular disease and death.

Author contributions

Conceptualization: Baoyu Geng, Zhe Liu.
Data curation: Baoyu Geng, Zhe Liu.
Formal analysis: Baoyu Geng, Zhe Liu.
Funding acquisition: Jun Jiang.
Investigation: Baoyu Geng, Zhe Liu.
Methodology: Guangzhi Feng.
Resources: Jun Jiang.
Software: Guangzhi Feng.
Supervision: Jun Jiang.
Validation: Guangzhi Feng.
Visualization: Guangzhi Feng.
Writing - original draft: Baoyu Geng.
Writing - review & editing: Jun Jiang.

References

[1] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13–20.
[2] Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009–19.
[3] Giacoppo D, Alfonso F, Xu B, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol 2020;75:2664–78.
[4] Nijhoff F, Agostoni P, Belkacemi A, et al. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: the nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial. Catheter Cardiovasc Interv 2015;86:534–44.
[5] Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo. J Am Coll Cardiol 2005;35:1969–76.
[6] Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv 2019;12:1691–9.
[7] Scheller B, Herhlein G, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxelcoated balloon catheter. Clin Res Cardiol 2008;97:773–81.
[8] Kobayashi N, Maehara A, Allocco D, et al. Stenting for STSegment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies. Coron Artery Dis 2014;25:575–81.
[9] Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015;386:65–64.
[10] Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. EuroIntervention 2015;11:926–34.
[11] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165.
[12] Gobić D, Tomulić V, Lulić D, et al. Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention: a feasibility study. Am J Med Sci 2017;354:553–60.
[13] Cai JZ, Zhu YX, Wang XY, et al. Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials. BMJ Open 2018;8: e017231.